CA2012257A1 - Anti-snoring formulations - Google Patents
Anti-snoring formulationsInfo
- Publication number
- CA2012257A1 CA2012257A1 CA 2012257 CA2012257A CA2012257A1 CA 2012257 A1 CA2012257 A1 CA 2012257A1 CA 2012257 CA2012257 CA 2012257 CA 2012257 A CA2012257 A CA 2012257A CA 2012257 A1 CA2012257 A1 CA 2012257A1
- Authority
- CA
- Canada
- Prior art keywords
- yohimbine
- formulation
- person
- snores
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT
A formulation for use to treat a person who snores when he or she sleeps, the said formulation comprising an effective amount of yohimbine (3 ?-15 ? -20.beta.-17? -hydroxy yohimbine-16?carboxylic acid methyl ester) and pharmaceutically tolerable forms thereof (for example, salts, esters and the like), in a pharmaceutically acceptable carrier.
A formulation for use to treat a person who snores when he or she sleeps, the said formulation comprising an effective amount of yohimbine (3 ?-15 ? -20.beta.-17? -hydroxy yohimbine-16?carboxylic acid methyl ester) and pharmaceutically tolerable forms thereof (for example, salts, esters and the like), in a pharmaceutically acceptable carrier.
Description
201~257 FIELD OF INVENTION
This invention relates to formulations suitable for treating snoring.
BACKGROUND OF THE INVENTION
Snoring is a very serious problem, not only for the individuals but also with the partner wlth whom such lndividual sleeps.
It is therefor an object of this invention to provide formulations suitable for use to treat persons who snore when they sleep and a method of treating such a person who snores when sleeping.
Further and other objects of the invention will be realized by those skilled in the art from the following summary of the invention and detailed description thereof.
SUMMARY OF THE INVENTION
According to one aspect of the invention a formulation is provided.for use to treat a person who snores when he or she sleeps, the said formulatlon comprising an effective amount of yohimbine (3c7~-15C~-20~-17G~-hydroxy yohimbine-16~C~carboxylic acid methyl ester) and pharmaceutically tolerable forms thereof (for example, salts, esters, and the like), in a pharmaceutically acceptable carrier. One formulation may comprise a compressed tablet which contains (1/12 gr.) 5.4 mg of yohimbine hydrochloride in a pharmaceutically tolerable carrier.
This formulation may be taken by the person suffering from snoring before bedtime.
According to another aspect of the invention an improved treatment for a person who snores may co~prise the administration to the patient, an effective amount of the yohimbine or any pharmaceutically tolerable thereof (for example, salts thereof [e.g. hydrochloride], esters, form and the like) in a pharmaceutically tolerable carrier for the treatment of snoring. Such process may, for example, comprise the administration of one tablet of (1/12 grain) 5.~ mg of yohimbine hydrochloride before bedtime.
One source of the yohimbine is found in a preparation Yocon (T.M.) manufactured by Palisades Pharmaceuticals Inc., Tenafly, New Jersey U.S.A 07670. A
distributor of the Yocon (T.M.) is Glenwood Laboratories Canada Limited, Mississauga, Ontario, L5T lH3.
Yohimbine is described in the literature [the Product monograph and "Effect of Yohimbine Hydrochloride On Erectile Impotence: A Double-Blind Study" The Journal of Uroloay Vol.
141, June] as an alpha adrenergic blocking agent having contraindications of renal or herpatic insufficiency. The user of the drug, according to the product monograph provided by the manufacturers of Yocon (T.M.) is warned under precautions that "Yohimbine may injure kidneys and cause hypotension. The possibility of a fatal overdose of yohimbine when associated with ingestion of alcohol must be considered. An overdose treatment is provided as follows:
"Conduct the gastric lavage and adMinister activated charcoal (four tablespoons: 500 ml of water). Treat excitation or convulsions with the barbituate".
For use as an alpha adrenergic blocking agent Yocon (T.M.) is to be administered to an adult one tablet up to 3 times daily or as directed by a physician. The tablets are white uncoated spherical tablets containing yohimbine hydrochloride 5.4 mg (1/12 grain), bottled in 100 or 1000.
The article entitled "Effect of Yohimbine _ 3 _ 20~Z~7 Hydrochloride on Erectile Impotence: A Double-Blind Study"
provides in the abstract that the 39% response by patients taking yohimbine hydrochloride on erectile dysfunction was encouraging.
By way of tests, Applicant has administered such a tablet (described above) of 1/12 grain (5.4 mg) of yohimbine hydrochloride to patients who snored when they slept prior to bedtime (e.g. one half hour). The partners of the patients did not detect any snoring through the night.
As many changes can be made to the invention without departing from the scope of the invention, it is intended that all material contained herein be interpreted as illustrative of the invention and not in a limiting sense.
This invention relates to formulations suitable for treating snoring.
BACKGROUND OF THE INVENTION
Snoring is a very serious problem, not only for the individuals but also with the partner wlth whom such lndividual sleeps.
It is therefor an object of this invention to provide formulations suitable for use to treat persons who snore when they sleep and a method of treating such a person who snores when sleeping.
Further and other objects of the invention will be realized by those skilled in the art from the following summary of the invention and detailed description thereof.
SUMMARY OF THE INVENTION
According to one aspect of the invention a formulation is provided.for use to treat a person who snores when he or she sleeps, the said formulatlon comprising an effective amount of yohimbine (3c7~-15C~-20~-17G~-hydroxy yohimbine-16~C~carboxylic acid methyl ester) and pharmaceutically tolerable forms thereof (for example, salts, esters, and the like), in a pharmaceutically acceptable carrier. One formulation may comprise a compressed tablet which contains (1/12 gr.) 5.4 mg of yohimbine hydrochloride in a pharmaceutically tolerable carrier.
This formulation may be taken by the person suffering from snoring before bedtime.
According to another aspect of the invention an improved treatment for a person who snores may co~prise the administration to the patient, an effective amount of the yohimbine or any pharmaceutically tolerable thereof (for example, salts thereof [e.g. hydrochloride], esters, form and the like) in a pharmaceutically tolerable carrier for the treatment of snoring. Such process may, for example, comprise the administration of one tablet of (1/12 grain) 5.~ mg of yohimbine hydrochloride before bedtime.
One source of the yohimbine is found in a preparation Yocon (T.M.) manufactured by Palisades Pharmaceuticals Inc., Tenafly, New Jersey U.S.A 07670. A
distributor of the Yocon (T.M.) is Glenwood Laboratories Canada Limited, Mississauga, Ontario, L5T lH3.
Yohimbine is described in the literature [the Product monograph and "Effect of Yohimbine Hydrochloride On Erectile Impotence: A Double-Blind Study" The Journal of Uroloay Vol.
141, June] as an alpha adrenergic blocking agent having contraindications of renal or herpatic insufficiency. The user of the drug, according to the product monograph provided by the manufacturers of Yocon (T.M.) is warned under precautions that "Yohimbine may injure kidneys and cause hypotension. The possibility of a fatal overdose of yohimbine when associated with ingestion of alcohol must be considered. An overdose treatment is provided as follows:
"Conduct the gastric lavage and adMinister activated charcoal (four tablespoons: 500 ml of water). Treat excitation or convulsions with the barbituate".
For use as an alpha adrenergic blocking agent Yocon (T.M.) is to be administered to an adult one tablet up to 3 times daily or as directed by a physician. The tablets are white uncoated spherical tablets containing yohimbine hydrochloride 5.4 mg (1/12 grain), bottled in 100 or 1000.
The article entitled "Effect of Yohimbine _ 3 _ 20~Z~7 Hydrochloride on Erectile Impotence: A Double-Blind Study"
provides in the abstract that the 39% response by patients taking yohimbine hydrochloride on erectile dysfunction was encouraging.
By way of tests, Applicant has administered such a tablet (described above) of 1/12 grain (5.4 mg) of yohimbine hydrochloride to patients who snored when they slept prior to bedtime (e.g. one half hour). The partners of the patients did not detect any snoring through the night.
As many changes can be made to the invention without departing from the scope of the invention, it is intended that all material contained herein be interpreted as illustrative of the invention and not in a limiting sense.
Claims (4)
1. A formulation for use to treat a person who snores when he or she sleeps, the said formulation comprising an effective amount of yohimbine (3 ?-15 ?-20.beta.-17?-hydroxy yohimbine-16 ?carboxylic acid methyl ester) and pharmaceutically tolerable forms thereof (for example, salts, esters and the like), in a pharmaceutically acceptable carrier.
2. The formulation of Claim 1, wherein the formulation comprises a compressed tablet which contains (1/12 of a gr.) 5.4 mg of yohimbine hydrochloride.
3. An improved treatment for a person who snores, the process comprises the administration prior to sleep to the patient of an effective amount of yohimbine or any pharmaceutically tolerable form thereof (for example, salts, esters and the like) in a pharmaceutically tolerable carrier.
4. The process of Claim 1, wherein the yohimbine may comprise a tablet of (1/12 grain) 5.4 mg of yohimbine hydrochloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2012257 CA2012257A1 (en) | 1990-03-15 | 1990-03-15 | Anti-snoring formulations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2012257 CA2012257A1 (en) | 1990-03-15 | 1990-03-15 | Anti-snoring formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2012257A1 true CA2012257A1 (en) | 1991-09-15 |
Family
ID=4144529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2012257 Abandoned CA2012257A1 (en) | 1990-03-15 | 1990-03-15 | Anti-snoring formulations |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2012257A1 (en) |
-
1990
- 1990-03-15 CA CA 2012257 patent/CA2012257A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW389696B (en) | Accelerated release composition containing bromocriptine | |
| TW416854B (en) | Buccal delivery of glucagon-like insulinotropic peptides | |
| FI945621A0 (en) | Regulated release formulation | |
| DE69521688D1 (en) | PHARMACEUTICAL Brewing Preparations Containing Biodegradable Microcapsules For Controlled Release Of Active Ingredients | |
| US5082665A (en) | Anti-snoring formulations using yohimbine | |
| IE872110L (en) | Oral therapeutic system having systemic action | |
| DE69519685D1 (en) | ORAL MEDICINAL PRODUCT WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES | |
| CZ176495A3 (en) | The use of riluzol for preparing a medicament suitable for treating parkinson's disease and parkinson's syndromes | |
| NO306894B1 (en) | Use of galanthamine for the preparation of a pharmaceutical formulation for the treatment of nicotine addiction | |
| UA27848C2 (en) | ORAL PHARMACEUTICAL FORM FOR THE TREATMENT OF CENTRAL STATES OF DOPAMIN DEFICIENCY | |
| JP3018160B2 (en) | Drug for reducing dysmenorrhea and / or premenstrual syndrome | |
| DE69922017D1 (en) | MEDICINAL PRODUCT AND METHOD FOR TREATING INTRACELLULAR INFECTIONS | |
| Weingart et al. | Analgesia with oral narcotics and added ibuprofen in cancer patients | |
| CA2012257A1 (en) | Anti-snoring formulations | |
| AR002727A1 (en) | THE USE OF RIDOGREL FOR THE MANUFACTURE OF A MEDICATION USEFUL FOR THE TREATMENT OF DIGESTIVE INFLAMMATORY DISEASES, A PHARMACEUTICAL COMPOSITION INCLUDING RIDOGREL AND A PROCEDURE FOR PREPARING SUCH COMPOSITION. | |
| JPH08239327A (en) | Agent for preventing or treating chronic skeletal muscle pain | |
| MX9800809A (en) | Process for preparing solid dosage forms of very low-dose drugs. | |
| Viukari et al. | Diazepam, promethazine and propiomazine as hypnotics in elderly inpatients | |
| KR100208969B1 (en) | Anti-ulcer agent containing glutinous rice extract | |
| Holt et al. | Intranasal β-agonist in allergic rhinitis. | |
| JPS6360926A (en) | Cold remedy | |
| Santaella et al. | A multicenter, randomized, double-blind study comparing once-daily bedtime administration of famotidine and ranitidine in the short-term treatment of active duodenal ulcer | |
| CA2187153A1 (en) | Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules | |
| Rcgcslcred | ercainaf~’ | |
| MY114610A (en) | Controlled drug delivery system for diltiazem. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |